CVRx (CVRX) Scheduled to Post Quarterly Earnings on Thursday

CVRx (NASDAQ:CVRXGet Rating) is scheduled to be announcing its earnings results after the market closes on Thursday, January 26th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. CVRx has set its FY 2022 guidance at EPS and its Q4 2022 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

CVRx (NASDAQ:CVRXGet Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. The business had revenue of $6.19 million for the quarter, compared to the consensus estimate of $5.87 million. CVRx had a negative net margin of 218.79% and a negative return on equity of 31.40%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Performance

Shares of CVRX opened at $14.56 on Wednesday. The company has a market capitalization of $299.70 million, a price-to-earnings ratio of -7.17 and a beta of 0.70. The company’s 50 day simple moving average is $14.89 and its 200 day simple moving average is $10.98. CVRx has a 1 year low of $4.60 and a 1 year high of $19.94.

Insider Buying and Selling

In related news, insider Paul Verrastro sold 4,600 shares of the company’s stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $11.94, for a total transaction of $54,924.00. Following the completion of the transaction, the insider now owns 4,400 shares of the company’s stock, valued at $52,536. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 25.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CVRx

Large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its position in shares of CVRx by 2.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 618,649 shares of the company’s stock worth $3,718,000 after acquiring an additional 14,173 shares in the last quarter. Vanguard Group Inc. increased its position in shares of CVRx by 17.7% in the first quarter. Vanguard Group Inc. now owns 463,935 shares of the company’s stock worth $2,779,000 after acquiring an additional 69,718 shares in the last quarter. BlackRock Inc. increased its position in shares of CVRx by 1.1% in the first quarter. BlackRock Inc. now owns 399,645 shares of the company’s stock worth $2,394,000 after acquiring an additional 4,233 shares in the last quarter. State Street Corp increased its position in shares of CVRx by 4.2% in the first quarter. State Street Corp now owns 247,656 shares of the company’s stock worth $1,483,000 after acquiring an additional 10,096 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of CVRx by 685.4% in the first quarter. Renaissance Technologies LLC now owns 188,500 shares of the company’s stock worth $1,129,000 after acquiring an additional 164,499 shares in the last quarter. Institutional investors and hedge funds own 51.16% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler upped their price objective on shares of CVRx from $14.00 to $18.50 in a research note on Monday, January 9th.

About CVRx

(Get Rating)

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.

See Also

Earnings History for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.